We are live on ! Find out more
JGC

J. Goldman & Co Portfolio holdings

AUM $3.44B
1-Year Est. Return 33.8%
This Fund
S&P 500
This Quarter Est. Return
+9.16%
1 Year Est. Return
+33.8%
3 Year Est. Return
+89.45%
5 Year Est. Return
+82.14%
10 Year Est. Return
+407.39%
AUM
$2.75B
AUM Growth
+$282M
Cap. Flow
+$98.4M
Cap. Flow %
3.57%
Top 10 Hldgs %
25.32%
Holding
537
New
191
Increased
80
Reduced
82
Closed
170

Top Sells

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$61.8M
2
TJX icon
TJX Companies
TJX
+$44.7M
3
UBER icon
Uber
UBER
+$43.5M
4
STZ icon
Constellation Brands
STZ
+$38M
5
PYPL icon
PayPal
PYPL
+$34.2M

Sector Composition

Rank Sector Weight
1 Technology 14.47%
2 Consumer Discretionary 12.59%
3 Industrials 10.36%
4 Healthcare 6.17%
5 Communication Services 3.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACAD icon
276
PUT
Acadia Pharmaceuticals
ACAD
$4.43B
$647K 0.02%
27,000
-13,500
-33% -$300K
XYZ
277
PUT
Block Inc
XYZ
$48.4B
$646K 0.02%
9,700
-18,000
-65% -$1.12M
TELL
278
CALL
DELISTED
Tellurian Inc.
TELL
$634K 0.02%
+449,900
New +$605K
KRYS icon
279
Krystal Biotech
KRYS
$10.1B
$628K 0.02%
5,349
+2,650
+98% +$271K
VRTX icon
280
Vertex Pharmaceuticals
VRTX
$121B
$616K 0.02%
+1,750
New +$590K
MNTK icon
281
Montauk Renewables
MNTK
$243M
$614K 0.02%
+82,536
New +$569K
CURV icon
282
Torrid Holdings
CURV
$254M
$607K 0.02%
215,845
-341,405
-61% -$1.09M
TOST icon
283
Toast
TOST
$18.7B
$593K 0.02%
+26,284
New +$525K
AMTX icon
284
Aemetis
AMTX
$106M
$588K 0.02%
+80,256
New +$305K
TREX icon
285
Trex
TREX
$4.51B
$577K 0.02%
8,802
-85,315
-91% -$4.76M
AGIO icon
286
CALL
Agios Pharmaceuticals
AGIO
$1.79B
$575K 0.02%
+20,300
New +$505K
SCPH
287
DELISTED
scPharmaceuticals
SCPH
$573K 0.02%
56,252
-11,250
-17% -$117K
MORF
288
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$538K 0.02%
9,379
+2,629
+39% +$137K
EPI icon
289
WisdomTree India Earnings Fund ETF
EPI
$2.06B
$522K 0.02%
+15,000
New +$497K
SLNO
290
DELISTED
Soleno Therapeutics
SLNO
$518K 0.02%
120,799
-148,644
-55% -$639K
FOUR icon
291
CALL
Shift4
FOUR
$4.2B
$509K 0.02%
+7,500
New +$492K
SNAP icon
292
Snap
SNAP
$7.89B
$480K 0.02%
+40,503
New +$407K
AVDL
293
DELISTED
Avadel Pharmaceuticals
AVDL
$474K 0.02%
28,773
-152,227
-84% -$1.98M
NWL icon
294
Newell Brands
NWL
$2.38B
$469K 0.02%
+53,876
New +$536K
FIGS icon
295
FIGS
FIGS
$1.79B
$465K 0.02%
56,258
+5,124
+10% +$39K
MREO
296
Mereo BioPharma
MREO
$54.7M
$463K 0.02%
350,985
-256,515
-42% -$298K
PCVX icon
297
Vaxcyte
PCVX
$7.81B
$452K 0.02%
9,051
+230
+3% +$10.9K
USO icon
298
CALL
United States Oil Fund
USO
$2.15B
$445K 0.02%
+7,000
New +$456K
MRSN
299
CALL
DELISTED
Mersana Therapeutics
MRSN
$444K 0.02%
+5,400
New +$790K
ISEE
300
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$438K 0.02%
11,136
-165,407
-94% -$5.84M

Similar funds

J. Goldman & Co's Q2 2023 Portfolio in Review

As of Q2 2023, J. Goldman & Co held 537 positions worth $2.75B, up 11% from $2.47B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

J. Goldman & Co deployed $98.4M of net new capital in Q2 2023, opening 191 new positions and adding to 80 existing holdings. Its largest new stake was Splunk Inc: 342,083 shares worth $36.3M.

By sector, the portfolio is most concentrated in Technology at 14% of assets, up from 14% a quarter earlier, followed by Consumer Discretionary and Industrials.

On the sell side, the largest reduction was Uber, an estimated $43.5M trimmed.

  • J. Goldman & Co's largest Q2 2023 buy was Splunk Inc: 342,083 shares worth $36.3M.
  • J. Goldman & Co added most to iShares Russell 2000 ETF in Q2 2023, an estimated $44.3M increase.
  • J. Goldman & Co's biggest Q2 2023 reduction was Uber, cutting an estimated $43.5M.
  • J. Goldman & Co fully exited Meta Platforms (Facebook) in Q2 2023, selling an estimated $61.8M.
  • J. Goldman & Co's ten largest holdings make up 25% of its $2.75B portfolio in Q2 2023.
  • J. Goldman & Co opened 191 new positions and closed 170 in Q2 2023.
  • J. Goldman & Co's portfolio value rose 11% quarter-over-quarter to $2.75B.

Based on J. Goldman & Co's 13F filing for Q2 2023, filed 14 Aug 2023.